soul trial oral semaglutide cardiovascular outcomes 2025 results A emulation in Nature Medicine shows that treatment with and tirzepatide showed similar levels of benefit on in people at elevated cardiovascular risk with obesity and diabetes. Link soul trial oral semaglutide cardiovascular
Description
The Regulatory Landscape: Current Context The GLP-1 telehealth space operates in an evolving regulatory environment
Research published in Cell Reports Medicine in 2026 concluded directly: weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function
As an isolated hormone, glucagon increases hepatic glucose production and could theoretically worsen glycemia
Once-daily liraglutide and the once-weekly agents can be taken at any time of day, whereas twice-daily exenatide and once-daily lixisenatide must be taken within 1 hour before eating (713)
